The vpriv market research report is one of a series of new reports that provides vpriv market statistics, including the vpriv industry global market size, regional shares, competitors with the vpriv market share, detailed vpriv market segments, market trends, and opportunities, and any further data you may need to thrive in the vpriv industry. This vpriv market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the increasing prevalence of rare diseases, the increasing number of products being approved, the increasing prevalence of genetic disorders, the rising demand for effective treatment options, and the growing awareness of rare genetic diseases. Major trends in the forecast period include growing focus on personalized medicine, increased adoption of patient-centric healthcare models, advancements in biologic manufacturing processes, the emergence of biosimilars, and increasing focus on sustainability in biologic drug production.
The increasing healthcare spending is expected to drive the growth of the Vpriv market in the future. This trend is fueled by factors such as aging populations, medical advancements, and the rising prevalence of chronic and rare diseases. As healthcare spending increases, it broadens access to advanced enzyme replacement therapies, making treatments such as Vpriv more affordable and accessible for patients with Gaucher disease type 1. It also supports investments in diagnostic and healthcare infrastructure, which are critical for addressing rare diseases. For example, in December 2023, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, an increase from 3.2% in 2021. This rise in healthcare expenditure is contributing to the growth of the Vpriv market.
The growing acceptance of biologics is also expected to drive the Vpriv market in the coming years. Biologics are medical treatments derived from living organisms, such as proteins, vaccines, and gene therapies, and are used to address a range of diseases. Their increased acceptance is due to their effectiveness in treating complex, chronic, and rare diseases with more targeted, personalized approaches. Vpriv fits into this trend by offering an enzyme replacement therapy designed specifically for Gaucher disease type 1, showcasing the role of biologics in treating genetic disorders. For instance, by the end of 2022, the U.S. Food and Drug Administration had approved 40 biosimilars, with 27 of them available in the U.S., reflecting the growing embrace of biologic treatments. This shift towards biologics is fueling the expansion of the Vpriv market.
The rise of personalized medicine is another factor driving the growth of the Vpriv market. Personalized medicine tailors treatments based on an individual’s genetic makeup, lifestyle, and health conditions, allowing for more precise and effective interventions. This approach is gaining momentum thanks to advancements in genomics and the ability to better target diseases based on genetic and biomarker profiles. Vpriv aligns with personalized medicine by providing a targeted enzyme replacement therapy tailored to the needs of individuals with Gaucher disease. In February 2023, the Personalized Medicine Coalition reported that in 2022, 12 personalized medicines were approved, accounting for 34% of all new drug approvals. This growth in personalized treatments is contributing to the expansion of the Vpriv market.
The countries covered in the vpriv market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vpriv (velaglucerase alfa) is a recombinant enzyme replacement therapy designed for the long-term treatment of Gaucher disease type 1, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. It works by replacing the missing or deficient enzyme, helping to reduce the accumulation of fatty substances and alleviate the symptoms associated with the disease.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Vpriv are type 1 Gaucher disease and type 3 Gaucher disease. Type 1 Gaucher disease is a rare genetic condition caused by a deficiency in glucocerebrosidase, the enzyme responsible for breaking down a fatty substance called glucocerebroside. Vpriv is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by a range of patients, including adults, pediatric, and geriatric populations.
The vpriv market consists of sales of infusion equipment, supportive care medications, diagnostic tools, and patient monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the increasing prevalence of rare diseases, the increasing number of products being approved, the increasing prevalence of genetic disorders, the rising demand for effective treatment options, and the growing awareness of rare genetic diseases. Major trends in the forecast period include growing focus on personalized medicine, increased adoption of patient-centric healthcare models, advancements in biologic manufacturing processes, the emergence of biosimilars, and increasing focus on sustainability in biologic drug production.
The increasing healthcare spending is expected to drive the growth of the Vpriv market in the future. This trend is fueled by factors such as aging populations, medical advancements, and the rising prevalence of chronic and rare diseases. As healthcare spending increases, it broadens access to advanced enzyme replacement therapies, making treatments such as Vpriv more affordable and accessible for patients with Gaucher disease type 1. It also supports investments in diagnostic and healthcare infrastructure, which are critical for addressing rare diseases. For example, in December 2023, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, an increase from 3.2% in 2021. This rise in healthcare expenditure is contributing to the growth of the Vpriv market.
The growing acceptance of biologics is also expected to drive the Vpriv market in the coming years. Biologics are medical treatments derived from living organisms, such as proteins, vaccines, and gene therapies, and are used to address a range of diseases. Their increased acceptance is due to their effectiveness in treating complex, chronic, and rare diseases with more targeted, personalized approaches. Vpriv fits into this trend by offering an enzyme replacement therapy designed specifically for Gaucher disease type 1, showcasing the role of biologics in treating genetic disorders. For instance, by the end of 2022, the U.S. Food and Drug Administration had approved 40 biosimilars, with 27 of them available in the U.S., reflecting the growing embrace of biologic treatments. This shift towards biologics is fueling the expansion of the Vpriv market.
The rise of personalized medicine is another factor driving the growth of the Vpriv market. Personalized medicine tailors treatments based on an individual’s genetic makeup, lifestyle, and health conditions, allowing for more precise and effective interventions. This approach is gaining momentum thanks to advancements in genomics and the ability to better target diseases based on genetic and biomarker profiles. Vpriv aligns with personalized medicine by providing a targeted enzyme replacement therapy tailored to the needs of individuals with Gaucher disease. In February 2023, the Personalized Medicine Coalition reported that in 2022, 12 personalized medicines were approved, accounting for 34% of all new drug approvals. This growth in personalized treatments is contributing to the expansion of the Vpriv market.
The key company operating in the vpriv market is Takeda Pharmaceutical Company Limited
North America was the largest region in the vpriv market in 2024. The regions covered in vpriv report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the vpriv market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vpriv (velaglucerase alfa) is a recombinant enzyme replacement therapy designed for the long-term treatment of Gaucher disease type 1, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. It works by replacing the missing or deficient enzyme, helping to reduce the accumulation of fatty substances and alleviate the symptoms associated with the disease.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Vpriv are type 1 Gaucher disease and type 3 Gaucher disease. Type 1 Gaucher disease is a rare genetic condition caused by a deficiency in glucocerebrosidase, the enzyme responsible for breaking down a fatty substance called glucocerebroside. Vpriv is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by a range of patients, including adults, pediatric, and geriatric populations.
The vpriv market consists of sales of infusion equipment, supportive care medications, diagnostic tools, and patient monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vpriv Market Characteristics4. Vpriv Market Trends And Strategies5. Vpriv Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Vpriv Pricing Analysis & Forecasts30. Global Vpriv Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vpriv Market32. Recent Developments In The Vpriv Market
3. Vpriv Market Biologic Drug Characteristics
6. Global Vpriv Growth Analysis And Strategic Analysis Framework
8. Vpriv Market Segmentation
9. Global Vpriv Epidemiology Of Clinical Indications
10. Vpriv Market Regional And Country Analysis
11. Asia-Pacific Vpriv Market
12. China Vpriv Market
13. India Vpriv Market
14. Japan Vpriv Market
15. Australia Vpriv Market
16. South Korea Vpriv Market
17. Western Europe Vpriv Market
18. UK Vpriv Market
19. Germany Vpriv Market
20. France Vpriv Market
21. Eastern Europe Vpriv Market
22. North America Vpriv Market
23. USA Vpriv Market
24. Canada Vpriv Market
25. South America Vpriv Market
26. Middle East Vpriv Market
27. Africa Vpriv Market
28. Vpriv Market Competitive Landscape And Company Profiles
29. Global Vpriv Market Pipeline Analysis
33. Vpriv Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Vpriv Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vpriv market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vpriv ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vpriv market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Type 1 Gaucher Disease; Type 3 Gaucher Disease2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
3) By End User: Adult; Pediatric; Geriatric
Key Companies Profiled: Takeda Pharmaceutical Company Limited
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Takeda Pharmaceutical Company Limited